Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs

European Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2011, Pages 463-470

  Pereira De Silva, Nahuel ^a   Piquioni, Paulo ^a   Kochen, Silvia ^a   Saidon, Patricia ^a  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

Adverse effects; Antiepileptic drugs; DRESS syndrome; Epilepsy; Hipersensitivity

Indexed keywords

ANTIHISTAMINIC AGENT; CARBAMAZEPINE; DIPHENHYDRAMINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LORATADINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DESCRIPTIVE RESEARCH; DRESS SYNDROME; DRUG ERUPTION; DRUG WITHDRAWAL; EOSINOPHILIA; EPILEPSY; FEMALE; FEVER; HUMAN; MACULOPAPULAR RASH; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DISEASE SUSCEPTIBILITY; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; EOSINOPHILIA; EXANTHEMA; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; RISK FACTORS; SYNDROME; TRIAZINES; YOUNG ADULT;

EID: 79955635812     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-011-1005-8     Document Type: Article

References (33)

1. Perucca E, Meador KJ (2005) Adverse effects of antiepileptic drugs. Acta Neurol Scand 112(Suppl 181):30-35
2. Zaccara G, Franciotta D, Perucca E (2007) Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48(7):1223-1244
3. Criado PR, Fachini Jardim Criado R, Vasconcellos C, de Oliveira Ramos R, Gonçalves AC (2004) Severe cutaneous adverse drug reactions - relevant aspects to diagnosis and treatment - Part II. An Bras Dermatol 79(5):587-601, set./out
4. Li L-F, Ma C (2006) Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 31:642-647
5. Bouquet H, Bagot M, Roujeau JC (1996) Drug induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinphilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1:250-257
6. Guidelines for the RegiSCAR Study. September 2009. Available at: http://regiscar.uni-freiburg.de/
7. Tennis P, Stern RS (1997) Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49:542-546
8. Roujeau J-C, Stern RS (1994) Severe adverse cutaneous reaction to drugs. N Engl J Med 10:1272-1285
9. Schlienger RG, Knowles SR, Shear NH (1998) Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 51:1172-1175
10. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156(3):609-611
11. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28-50
12. Girolomoni G, Gisondi P, Ottaviani C, Cavani A (2004) Immunoregulation of allergic contact dermatitis. J Dermatol 31(4):264-270
13. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK (2003) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63:732-741
14. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK (2003) Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 111:1393-1403
15. Kim C-W, Choi G-S, Yun Chang-Ho, Kim Deok-In (2006) Drug hypersensitivity to previously tolerated phenytoin by carbamazepine-induced DRESS syndrome. J Korean Med Sci 21:768-772
16. Klassen BD, Sadler RM (2001) Induction of hipersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia 42(3):433-435
17. Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A (2010) Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermat 62(1):47-53
18. Cervigón GI, Sandín SS, Pérez HC, Bahillo MC, Vélez PC, García Almagro D (2006) Síndrome de DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) por sulfonamidas. Med Cutan Iber Lat Am 34(3):120-126
19. Tohyama M, Yahata Y, Yasukawa M et al (1998) Severe hypersensitivity syndrome due to sulfalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134:1113-1117
20. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T (1998) Human herpesvirus 6 infection as a risk factor for the development of severe drug induced hypersensitivity syndrome. Arch Dermatol 134:1108-1112
21. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, Beilachs S, Crickx B (2001) Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 137:301-304
22. Hashimoto K, YasukawaM, Tohyama M(2003) Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol 3:255-260
23. Pitche P, Padonou CS, Kombate K et al (2005) Stevens-Johnson syndrome and toxic epidermal necrolysis in Lome (Togo). Evolutional and etiological profiles of 40 cases. Ann Dermatol Venereol 132(6-7 Pt 1):531-534
24. Schopf E, Stuhmer A, Rzany B et al (1991) Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 127:839-842
25. Peyrière H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac J-P, Buys DH (2006) Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Therapeutics 155:422-428
26. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, y Perucca E, SOPHIE Study Group (2010) Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 51(5):797-804
27. Centre for Drug Evaluation and Research (CDER) (1997) Glaxo-Wellcome Lamictal Advisory Board Briefing Document, October 23. Glaxo-Wellcome
28. Guberman A, Besag F, Brodie M, Dooley J, Duchowny M, Pellock J, Richens A, Stern R, Trevathan E (1999) Lamotrigine-associated rash: risk benefit considerations in adults and children. Epilepsia 40(7):985-999, I
29. Messenheimer J, Mullens EL, Giorgi L, Young F (1998) Safety review of adult clinical trial experience with lamotrigine. Drug Saf 18:281-296
30. Anderson GD (2002) Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43(Suppl 3):53-59
31. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR Jr (2006) Predictors of Lamotrigine-associated rash. Epilepsia 47:318-322
32. Fitton A, Goa KL (1995) Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691-713
33. Federal Drug Administration. Available at: http://www.fda.com